Fund moves
33 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 27, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 26, 2026 · Filed Mar 28, 2026
The CEO of United Therapeutics sold $447K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$447,479
Shares × reported transaction price
29 days after results of Feb 25, 2026, 41 days before results of May 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $532.53 on Mar 26, 2026, within 3% of its 52-week high, after a 12% rise over the previous 30 trading days
52-week range $274.70 (Jul 31, 2025) to $544.71 (Mar 11, 2026), 95% of the way up, from 251 adjusted closes. 30 trading days earlier: $475.85 on Feb 11, 2026. Describes the past only, not a forecast
RSI 57, 27% above its 200-day average, 8% above its 50-day average, 2% below the 52-week high, 20-day volatility 44% a year, against the S&P 500: +6 points over 1 month, +11 points over 3 months, +24 points over 6 months
From the adjusted closes up to Mar 26, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.9% | +4.3% | −9.2% |
| 30 days | −2.9% | +12.6% | −15.5% |
| 90 days | −7.4% | +17.3% | −24.6% |
| 180 days | −17.5% | +21.1% | −38.6% |
Past results only. Not a forecast.
Fund moves
33 tracked managers disclosed the same change for Q1 2026. From a 13F filed Apr 27, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Apr 23 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$159K of United Therapeutics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.